Literature DB >> 8505393

Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: Medical, socioeconomic, and legal issues. Selecting the antibiotic.

W A Craig1.   

Abstract

Variations in antibiotic pharmacokinetics and pharmacodynamics allow therapy to be readily adapted to the outpatient setting. Factors to be taken into account when designing an outpatient parenteral regimen include minimal inhibitory and bactericidal concentrations, post-antibiotic effect, half-life, protein binding, drug stability, IM versus i.v. administration, and continuous versus intermittent infusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8505393     DOI: 10.1080/21548331.1993.11442930

Source DB:  PubMed          Journal:  Hosp Pract (Off Ed)        ISSN: 8750-2836


  6 in total

1.  Infusion phlebitis: relative incidence associated with cefuroxime administered by intermittent and continuous infusion.

Authors:  C A Owens; P G Ambrose; R Quintiliani; C H Nightingale; D P Nicolau
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

2.  Retain intermittent dosing of carbapenems.

Authors:  H Hanberger; L E Nilsson
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

Review 3.  Ambulatory use of parenteral antibacterials: contemporary perspectives.

Authors:  J E Leggett
Journal:  Drugs       Date:  2000       Impact factor: 9.546

4.  Intravenous antimicrobial therapy in the community: underused, inadequately resourced, or irrelevant to health care in Britain?

Authors:  D Nathwani; P Davey
Journal:  BMJ       Date:  1996-12-14

Review 5.  Antibiotic selection factors and description of a hospital-based outpatient antibiotic therapy program in the USA.

Authors:  W A Craig
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-07       Impact factor: 3.267

6.  Pharmacokinetics and pharmacodynamics of newer oral cephalosporins: implications for treatment of community-acquired lower respiratory tract infections.

Authors:  M Cazzola; M G Matera; C F Donner
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.